Goodwin Investment Advisory’s iBio IBIO Stock Holding History

Goodwin Investment Advisory’s Portfolio IBIO Stock Details IBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-2	Closed	-$1K	–	140
2020 Q4	$1K	Buy	+2	New	+$1.63K	﹤0.01%	89

Other funds holding IBIO

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Goodwin Investment Advisory's IBIO Position: Q1 2021 in Review

Goodwin Investment Advisory sold out of iBio (IBIO) in Q1 2021, closing a stake of 2 shares — an estimated $1K sold.

Goodwin Investment Advisory first reported a position in IBIO in Q4 2020 and held it in 1 quarter. The position peaked at $1K in Q4 2020. 91 funds tracked by Wall St. Rank hold IBIO as of Q1 2021.

Goodwin Investment Advisory reported no remaining iBio position as of Q1 2021 after selling out during the quarter.
Goodwin Investment Advisory sold 2 iBio shares in Q1 2021, an estimated $1K.
Goodwin Investment Advisory first reported a position in iBio in Q4 2020 and held it in 1 quarter.
Goodwin Investment Advisory's iBio position peaked at $1K in Q4 2020.
91 funds tracked by Wall St. Rank held iBio as of Q1 2021.

Based on Goodwin Investment Advisory's 13F filing for Q1 2021, filed 5 May 2021.